Russian production of medicines for cancer began in Khimki

Russian import and production of innovative medicines, including cancer, officially opened on March 19 in Khimki, on the base of "BioIntegrator" — a biopharmaceutical company, part of the Center of High Technologies "KhimRar." One of the first drugs produced "BioIntegratorom" became rituximab — a drug to treat certain types of cancer and autoimmune diseases.

The first product will be released later this year. Given the complexity of the process, so production time is fast enough. The other drugs, including anti-oncology, will appear on the Russian market in two years.

Altogether the "BioIntegratora" 12 drugs — 9 import and innovative 3.

Manufacturing site BioIntegratora — is 700 square meters. m clean room built according to the standard GMP. It is a full cycle of biotech drugs: from cell bank of producers to production.

 BioIntegrator develops widely used reproduced and original biotech drugs used in the treatment of cancer, such as Hodgkin’s lymphoma and autoimmune diseases such as rheumatoid arthritis. Production reproduced biotech drugs will make them more affordable than originator medicines and expand their use in Russia.
Among the original products developed by the company occupies a special place on the basis of drug Auriksin antibody conjugate. Created with the support of the Ministry of Industry and Trade of this unique product, which showed high efficacy in pre-clinical studies may provide a chance for patients with severe forms of non-Hodgkin’s lymphomas.

Like this post? Please share to your friends: